High dose androgen therapy in male pseudohermaphroditism due to 5α-reductase deficiency and disorders of the androgen receptor

P. Price, J. A H Wass, Jim Griffin III, M. Leshin, M. O. Savage, D. M. Large, D. E. Bu'Lock, D. C. Anderson, J. D. Wilson, G. M. Besser

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

We describe the clinical and biochemical features of six men with male pseudohermaphroditism due to androgen resistance. Each of the subjects had male-gender behavior but incomplete virilization. The underlying defects in androgen metabolism were defined by studies of the 5α-reductase enzyme and the androgen receptor in fibroblasts cultured from biopsies of genital skin. Four of the six have 5α-reductase deficiency, and two have defects of the androgen receptor (the Reifenstein syndrome). The responses of these men to androgen treatment were assessed by monitoring nitrogen balance, plasma luteinizing hormone (LH) values, and clinical parameters of virilization including penile growth, potency and ejaculatory volume, muscle bulk, and growth of body and facial hair. In all of the subjects with 5α-reductase deficiency and one man with the Reifenstein syndrome significant response occurred, as evidenced by nitrogen retention, lowered plasma LH levels, and improved virilization, with doses of parenteral testosterone esters that raised plasma testosterone levels above the normal male range and brought plasma dihydrotestosterone levels into the normal male range. The subject who did not respond with clinical virilization nevertheless showed nitrogen retention in response to acute testosterone administration. This patient had a profound deficiency of the androgen receptor, whereas the man with a receptor defect who did respond clinically to therapy had normal amounts of a qualitatively abnormal receptor. We conclude that high dose androgen therapy may be of benefit in improving virilization, self-image, and sexual performance in subjects with 5α-reductase-deficiency who have male-gender behavior and in some subjects with defects of the androgen receptor.

Original languageEnglish (US)
Pages (from-to)1496-1508
Number of pages13
JournalJournal of Clinical Investigation
Volume74
Issue number4
StatePublished - 1984

Fingerprint

XY Disorders of Sex Development 46
Androgen-Insensitivity Syndrome
Virilism
Androgens
Oxidoreductases
Androgen Receptors
Testosterone
Nitrogen
Luteinizing Hormone
Reference Values
Therapeutics
Dihydrotestosterone
Growth
Hair
Esters
Fibroblasts
Biopsy
Muscles
Skin
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

High dose androgen therapy in male pseudohermaphroditism due to 5α-reductase deficiency and disorders of the androgen receptor. / Price, P.; Wass, J. A H; Griffin III, Jim; Leshin, M.; Savage, M. O.; Large, D. M.; Bu'Lock, D. E.; Anderson, D. C.; Wilson, J. D.; Besser, G. M.

In: Journal of Clinical Investigation, Vol. 74, No. 4, 1984, p. 1496-1508.

Research output: Contribution to journalArticle

Price, P, Wass, JAH, Griffin III, J, Leshin, M, Savage, MO, Large, DM, Bu'Lock, DE, Anderson, DC, Wilson, JD & Besser, GM 1984, 'High dose androgen therapy in male pseudohermaphroditism due to 5α-reductase deficiency and disorders of the androgen receptor', Journal of Clinical Investigation, vol. 74, no. 4, pp. 1496-1508.
Price, P. ; Wass, J. A H ; Griffin III, Jim ; Leshin, M. ; Savage, M. O. ; Large, D. M. ; Bu'Lock, D. E. ; Anderson, D. C. ; Wilson, J. D. ; Besser, G. M. / High dose androgen therapy in male pseudohermaphroditism due to 5α-reductase deficiency and disorders of the androgen receptor. In: Journal of Clinical Investigation. 1984 ; Vol. 74, No. 4. pp. 1496-1508.
@article{f2d180362fd749d6b65e01deaf8bd8f0,
title = "High dose androgen therapy in male pseudohermaphroditism due to 5α-reductase deficiency and disorders of the androgen receptor",
abstract = "We describe the clinical and biochemical features of six men with male pseudohermaphroditism due to androgen resistance. Each of the subjects had male-gender behavior but incomplete virilization. The underlying defects in androgen metabolism were defined by studies of the 5α-reductase enzyme and the androgen receptor in fibroblasts cultured from biopsies of genital skin. Four of the six have 5α-reductase deficiency, and two have defects of the androgen receptor (the Reifenstein syndrome). The responses of these men to androgen treatment were assessed by monitoring nitrogen balance, plasma luteinizing hormone (LH) values, and clinical parameters of virilization including penile growth, potency and ejaculatory volume, muscle bulk, and growth of body and facial hair. In all of the subjects with 5α-reductase deficiency and one man with the Reifenstein syndrome significant response occurred, as evidenced by nitrogen retention, lowered plasma LH levels, and improved virilization, with doses of parenteral testosterone esters that raised plasma testosterone levels above the normal male range and brought plasma dihydrotestosterone levels into the normal male range. The subject who did not respond with clinical virilization nevertheless showed nitrogen retention in response to acute testosterone administration. This patient had a profound deficiency of the androgen receptor, whereas the man with a receptor defect who did respond clinically to therapy had normal amounts of a qualitatively abnormal receptor. We conclude that high dose androgen therapy may be of benefit in improving virilization, self-image, and sexual performance in subjects with 5α-reductase-deficiency who have male-gender behavior and in some subjects with defects of the androgen receptor.",
author = "P. Price and Wass, {J. A H} and {Griffin III}, Jim and M. Leshin and Savage, {M. O.} and Large, {D. M.} and Bu'Lock, {D. E.} and Anderson, {D. C.} and Wilson, {J. D.} and Besser, {G. M.}",
year = "1984",
language = "English (US)",
volume = "74",
pages = "1496--1508",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",

}

TY - JOUR

T1 - High dose androgen therapy in male pseudohermaphroditism due to 5α-reductase deficiency and disorders of the androgen receptor

AU - Price, P.

AU - Wass, J. A H

AU - Griffin III, Jim

AU - Leshin, M.

AU - Savage, M. O.

AU - Large, D. M.

AU - Bu'Lock, D. E.

AU - Anderson, D. C.

AU - Wilson, J. D.

AU - Besser, G. M.

PY - 1984

Y1 - 1984

N2 - We describe the clinical and biochemical features of six men with male pseudohermaphroditism due to androgen resistance. Each of the subjects had male-gender behavior but incomplete virilization. The underlying defects in androgen metabolism were defined by studies of the 5α-reductase enzyme and the androgen receptor in fibroblasts cultured from biopsies of genital skin. Four of the six have 5α-reductase deficiency, and two have defects of the androgen receptor (the Reifenstein syndrome). The responses of these men to androgen treatment were assessed by monitoring nitrogen balance, plasma luteinizing hormone (LH) values, and clinical parameters of virilization including penile growth, potency and ejaculatory volume, muscle bulk, and growth of body and facial hair. In all of the subjects with 5α-reductase deficiency and one man with the Reifenstein syndrome significant response occurred, as evidenced by nitrogen retention, lowered plasma LH levels, and improved virilization, with doses of parenteral testosterone esters that raised plasma testosterone levels above the normal male range and brought plasma dihydrotestosterone levels into the normal male range. The subject who did not respond with clinical virilization nevertheless showed nitrogen retention in response to acute testosterone administration. This patient had a profound deficiency of the androgen receptor, whereas the man with a receptor defect who did respond clinically to therapy had normal amounts of a qualitatively abnormal receptor. We conclude that high dose androgen therapy may be of benefit in improving virilization, self-image, and sexual performance in subjects with 5α-reductase-deficiency who have male-gender behavior and in some subjects with defects of the androgen receptor.

AB - We describe the clinical and biochemical features of six men with male pseudohermaphroditism due to androgen resistance. Each of the subjects had male-gender behavior but incomplete virilization. The underlying defects in androgen metabolism were defined by studies of the 5α-reductase enzyme and the androgen receptor in fibroblasts cultured from biopsies of genital skin. Four of the six have 5α-reductase deficiency, and two have defects of the androgen receptor (the Reifenstein syndrome). The responses of these men to androgen treatment were assessed by monitoring nitrogen balance, plasma luteinizing hormone (LH) values, and clinical parameters of virilization including penile growth, potency and ejaculatory volume, muscle bulk, and growth of body and facial hair. In all of the subjects with 5α-reductase deficiency and one man with the Reifenstein syndrome significant response occurred, as evidenced by nitrogen retention, lowered plasma LH levels, and improved virilization, with doses of parenteral testosterone esters that raised plasma testosterone levels above the normal male range and brought plasma dihydrotestosterone levels into the normal male range. The subject who did not respond with clinical virilization nevertheless showed nitrogen retention in response to acute testosterone administration. This patient had a profound deficiency of the androgen receptor, whereas the man with a receptor defect who did respond clinically to therapy had normal amounts of a qualitatively abnormal receptor. We conclude that high dose androgen therapy may be of benefit in improving virilization, self-image, and sexual performance in subjects with 5α-reductase-deficiency who have male-gender behavior and in some subjects with defects of the androgen receptor.

UR - http://www.scopus.com/inward/record.url?scp=0021750195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021750195&partnerID=8YFLogxK

M3 - Article

C2 - 6480833

AN - SCOPUS:0021750195

VL - 74

SP - 1496

EP - 1508

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 4

ER -